Key Points
- Patricia Carr, Jazz Pharmaceuticals' CAO, sold 4,660 shares on Dec. 5 at an average price of $171.20 for $797,792, reducing her stake by 39.92% and leaving her with 7,012 shares valued at ~$1.20M.
- She also sold 5,319 shares on Nov. 18 at an average of $182.06 for about $968,377.
- Market context: JAZZ opened at $162.26 (down ~4%), with a 12‑month range of $95.49–$182.99, institutional ownership ~89.14%, and a consensus rating of "Moderate Buy" with a $195.67 price target.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares in the company, valued at $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Patricia Carr also recently made the following trade(s):
- On Tuesday, November 18th, Patricia Carr sold 5,319 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $182.06, for a total transaction of $968,377.14.
Jazz Pharmaceuticals Stock Down 4.0%
Shares of JAZZ stock opened at $162.26 on Wednesday. The stock has a 50 day moving average of $149.25 and a 200 day moving average of $128.19. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. The stock has a market cap of $9.86 billion, a P/E ratio of -26.73, a P/E/G ratio of 3.80 and a beta of 0.30. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99.
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of JAZZ. Cetera Investment Advisers raised its stake in shares of Jazz Pharmaceuticals by 4.4% in the 1st quarter. Cetera Investment Advisers now owns 10,536 shares of the specialty pharmaceutical company's stock worth $1,308,000 after buying an additional 444 shares in the last quarter. LPL Financial LLC increased its position in shares of Jazz Pharmaceuticals by 14.5% in the first quarter. LPL Financial LLC now owns 25,769 shares of the specialty pharmaceutical company's stock worth $3,199,000 after acquiring an additional 3,264 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $203,000. PNC Financial Services Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 8.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,128 shares of the specialty pharmaceutical company's stock valued at $637,000 after acquiring an additional 379 shares in the last quarter. Finally, Townsquare Capital LLC boosted its stake in Jazz Pharmaceuticals by 12.0% in the 1st quarter. Townsquare Capital LLC now owns 3,966 shares of the specialty pharmaceutical company's stock worth $492,000 after purchasing an additional 426 shares during the period. 89.14% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of analysts recently issued reports on JAZZ shares. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the company an "outperform" rating in a research note on Monday, November 17th. UBS Group restated a "neutral" rating and set a $188.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Needham & Company LLC reissued a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a research note on Monday. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $195.67.
View Our Latest Stock Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
